England's National Health Service will soon offer nivolumab as a quick injection for cancer patients. This new method cuts ...

Participants received 480 mg of nivolumab and 160 mg of relatlimab intravenously once every 4 weeks for two cycles before ...

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...

University of Southern California researchers have found a way to rebrand this oft-embarrassing sore subject by genetically ...

Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant ...

The herpes simplex virus type 1 (HSV-1), which affects almost two‑thirds of the world's population and is generally ...

A cancer-killing virus could soon be approved for use after shrinking tumours in a third of people with late-stage melanoma ...

Gynecological clear cell cancers (CCCs), very aggressive forms of ovarian and endometrial malignancies, respond poorly to chemotherapy.  The low respo | Cancer ...

Findings from a Phase I trial initiated by Dana-Farber Cancer Institute have demonstrated that the NeoVax personalised cancer ...

Modified Herpes Virus as a Weapon Against Skin Cancer? A new study suggests it might work—even for metastases deep within the ...

The complete remission of a testicular cancer patient receiving Mink Therapeutics Inc.’s allogeneic, off-the-shelf invariant natural killer T-cell therapy Agent-797 with nivolumab drove the company’s ...